Get the Stockscreener App
9.49
4.04%
-0.40
Candel Therapeutics Inc stock is traded at $9.49, with a volume of 1.19M.
It is down -4.04% in the last 24 hours and up +13.65% over the past month.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$9.89
Open:
$9.85
24h Volume:
1.19M
Relative Volume:
0.58
Market Cap:
$695.33M
Revenue:
$31,000
Net Income/Loss:
$-54.42M
P/E Ratio:
-9.7055
EPS:
-0.9778
Net Cash Flow:
$-48.99M
1W Performance:
-3.46%
1M Performance:
+13.65%
6M Performance:
+66.20%
1Y Performance:
+54.31%
1-Day Range:
$9.215
$9.86
1-Week Range:
$9.215
$10.45
52-Week Range:
$4.35
$11.36
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
9.49 | 695.33M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 8, 2026 - marketscreener.com
Form 4 Candel Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
[Form 4] Candel Therapeutics, Inc. Insider Trading Activity - Stock Titan
Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3 - Stock Titan
Candel hands its new commercial chief 285,000 options - Stock Titan
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
Insider Sell: Francesca Barone Sells Shares of Candel Therapeuti - GuruFocus
Candel Therapeutics CSO Francesca Barone sells $235k in stock By Investing.com - Investing.com Australia
Candel Therapeutics CSO Francesca Barone sells $235k in stock - Investing.com
Form 4 Candel Therapeutics Inc For: 1 July By Investing.com - Investing.com UK
Candel Therapeutics (CADL) CSO executes 23,447-share open-market sale under 10b5-1 plan - Stock Titan
Candel Therapeutics (CADL) CTO sells 7,000 shares in planned trade - Stock Titan
Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options - Stock Titan
Candel Therapeutics (CADL) director receives fully vested option award - Stock Titan
Candel Therapeutics (CADL) director receives fully vested 381-option equity grant - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel grants new employee 25,000 stock options at $10.30 - Stock Titan
Candel Therapeutics initiates phase 3 lung cancer trial By Investing.com - Investing.com South Africa
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’ - TradingView
Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug - marketscreener.com
Candel Therapeutics initiates phase 3 lung cancer trial - Investing.com
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - The Manila Times
Candel opens global phase 3 AURORA trial in lung cancer - Stock Titan
[144] Candel Therapeutics, Inc. SEC Filing - Stock Titan
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Price to sales forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Enterprise value to EBITDA forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Candel Therapeutics, Inc. Actuals & Estimates (NASDAQ:CADL) - TradingView
Enterprise value to EBITDA forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
Enterprise value to revenue forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Enterprise value to EBIT forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Price to earnings forward of Candel Therapeutics, Inc. – NASDAQ:CADL - TradingView
Candel Therapeutics, Inc. Actuals & Estimates (BOATS:CADL) - TradingView
Price to earnings forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
Enterprise value to revenue forward of Candel Therapeutics, Inc. – BOATS:CADL - TradingView
$Candel Therapeutics (CADL.US)$ [Fireworks]New 52 Week High[Fireworks] 9.75 [Twirl][Twirl][Twirl] - Moomoo
CADL Forecast — Price Target — Prediction for 2027 - TradingView
Candel Therapeutics Designates Mark Sims as CCO - Yahoo Finance
Candel Therapeutics names Mark Sims as chief commercial officer By Investing.com - Investing.com Australia
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Ahead of Planned BLA Filing - citybiz
Candel Therapeutics names Mark Sims as chief commercial officer - Investing.com
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - The Manila Times
Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 - marketscreener.com
Candel Therapeutics, Inc. Files Form 8-K with SEC Detailing Corporate Information and Emerging Growth Status - Minichart
Candel Therapeutics Stockholders Approve Directors and Auditor - TipRanks
Form 4 Candel Therapeutics Inc For: 24 June By Investing.com - Investing.com South Africa
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):